Charity Lifearc Hauls in $1.3B For Keytruda To Boost Translational Efforts
U.K. bioscience is due for a huge injection of cash after the technology commercialization arm of the Medical Research Council, Lifearc, sold off a portion of its future royalty stream to Merck & Co. Inc.'s Keytruda (pembrolizumab) for $1.297 billion. The transaction propels Lifearc into the top echelon of U.K. medical charities by size of its investment fund and will allow it to vastly expand its role in translating publicly funded research into new therapies.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063